Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Tenax Therapeutics, Inc.NASDAQ: TENX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$383.17M, compared with -$325.26M a year earlier.
Context
- Retained earnings amounted to 311.1% of total assets at the end of Q1 FY2026, up 20.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -17.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (367.45M) USD
- Year-over-year change
- -16.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (367.45M) | -16.7% |
| FY2024 | 2024-12-31 | (314.86M) | -5.9% |
| FY2023 | 2023-12-31 | (297.25M) | -2.7% |
| FY2022 | 2022-12-31 | (289.54M) | -4.0% |
| FY2021 | 2021-12-31 | (278.49M) | — |
Retained Earnings vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 retained earnings of -$383.17M is the 6th highest of the 7 companies compared; the peer median is -$262.1M.
- Its year-over-year change of -17.8% is the 5th highest of 7, against a peer median of -12.6%.
- Retained earnings amounts to 311.1% of total assets for TENX, versus a peer median of 240.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | -$152.26M | -9.2% | — | 63.9% | |
| Mar 2026 | -$212.6M | +13.5% | — | 333.9% | |
| Mar 2026 | -$250.98M | -16.0% | — | 286.9% | |
| Mar 2026 | -$273.22M | -25.8% | — | 193.8% | |
| Mar 2026 | -$334.6M | -5.6% | — | 862.7% | |
| Mar 2026 | -$383.17M | -17.8% | — | 311.1% | |
| Jun 2026 | -$796.74M | -98.0% | — | 0.8% | |
| Peer median (excluding TENX) | -$262.1M | -12.6% | — | 240.3% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.